Busca un médico

Lance C. Pagliaro, M.D.

  1. Oncologist
Solicite una Consulta

Publicaciones

  1. Tekin B, Cubilla AL, Cheville JC, Smith CY, Jenkins SM, Dasari S, Enninga EAL, Norgan AP, Menon S, Whaley RD, Hernandez LH, Jimenez RE, Garcia JJ, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Pagliaro LC, Erickson LA, Guo R, Gupta S. High-risk human papilloma virus status & outcomes for penile squamous cell carcinoma: A single institution experience. Hum Pathol. 2024 Aug; 150:9-19 Epub 2024 June 21
    View PubMed
  2. Rose KM, Pham R, Zacharias NM, Ionescu F, Paravathaneni M, Marchetti KA, Sanchez D, Mustasam A, Sandstrom R, Vikram R, Dhillon J, Rao P, Schneider A, Pagliaro L, Alifrangis C, Albersen M, Roussel E, Master VA, Nazha B, Hernandez C, Moses KA, Protzel C, Montgomery J, Angel M, Tobias-Machado M, Spiess PE, Pettaway CA, Chahoud J. Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study. J Natl Cancer Inst. 2024 Jun 7; 116 (6):966-973
    View PubMed
  3. Tekin B, Sali AP, Menon S, Cheville JC, Smith CY, Jenkins SM, Dasari S, Enninga EAL, Norgan AP, Cubilla AL, Whaley RD, Hernandez LH, Jimenez RE, Garcia JJ, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Pagliaro LC, Erickson LA, Guo R, Gupta S. Comparison of a modified staging system with 8th edition AJCC criteria in a North American cohort of pT2/pT3 HPV-negative penile squamous cell carcinoma. Hum Pathol. 2024 Jun; 148:81-86 Epub 2024 May 22
    View PubMed
  4. Pagliaro LC, Tekin B, Gupta S, Herrera Hernandez L. Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside. Cancers (Basel). 2024 May 30; 16 (11)
    View PubMed
  5. Joyce DD, Sharma V, Wymer KM, Moriarty JP, Borah BJ, Walia A, Costello BA, Pagliaro LC, Daneshmand S, Leibovich BC, Boorjian SA. Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma. J Natl Cancer Inst. 2024 Mar 7; 116 (3):468-475
    View PubMed
  6. Sachdeva A, McGuinness L, Zapala L, Greco I, Garcia-Perdomo HA, Kailavasan M, Antunes-Lopes T, Ayres B, Barreto L, Campi R, Crook J, Johnstone P, Kumar V, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Protzel C, Bryan Rumble R, Sanchez Martinez DF, Spiess PE, Tagawa ST, van der Heijden MS, Parnham AS, Pettaway CA, Albersen M, Sangar VK, Brouwer OR, Sakalis VI. Management of Lymph Node-positive Penile Cancer: A Systematic Review. Eur Urol. 2024 Mar; 85 (3):257-273 Epub 2023 May 18
    View PubMed
  7. Dasari S, McCarthy MR, Wojcik AA, Pitel BA, Samaddar A, Tekin B, Whaley RD, Raghunathan A, Hernandez LH, Jimenez RE, Stish BJ, Thompson RH, Leibovich BC, Boorjian SA, Jeffrey Karnes R, Childs DS, Quevedo JF, Kwon ED, Pagliaro LC, Costello BA, Halling KC, Cheville JC, Kipp BR, Gupta S. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer Prostatic Dis. 2024 Feb 27. [Epub ahead of print]
    View PubMed
  8. Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2024 Feb 10 [Epub ahead of print]
    View PubMed
  9. Greco I, Fernandez-Pello S, Sakalis VI, Barreto L, Albersen M, Ayres B, Antunes Lopes T, Campi R, Crook J, Garcia Perdomo HA, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Parnham AS, Pettaway CA, Protzel C, Rumble RB, Sachdeva A, Sanchez Martinez DF, Zapala L, Tagawa ST, Spiess PE, Brouwer OR. Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma. Eur Urol Focus. 2023 Dec 8 Epub 2023 Dec 08
    View PubMed
  10. Tekin B, Cheville JC, Herrera Hernandez L, Negron V, Smith CY, Jenkins SM, Dasari S, Enninga EAL, Norgan AP, Menon S, Cubilla AL, Whaley RD, Jimenez RE, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Pagliaro LC, Erickson LA, Guo R, Gupta S. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. Hum Pathol. 2023 Dec; 142:42-50 Epub 2023 Nov 15
    View PubMed
  11. Rodrigues Pessoa R, Zhang H, Zganjar A, Nabavizadeh R, Packiam VT, Lohse CM, Cheville JC, Pagliaro LC, Costello BA, Boorjian SA, Thompson RH, Lucien F, Dong H, Leibovich BC. Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery. Urol Oncol. 2023 Sep; 41 (9):393.e1-393.e7 Epub 2023 July 04
    View PubMed
  12. May M, Lebentrau S, Watkin N, Albersen M, Protzel C, Chahoud J, Brouwer OR, Pettaway CA, Pagliaro LC, Necchi A, Hakenberg OW, Ayres B, Spiess PE. [Initial presentation of the Pentafecta score as a quality instrument for outcome evaluation of primary surgical treatment in patients with penile cancer]. Aktuelle Urol. 2023 Aug; 54 (4):292-298 Epub 2023 June 20
    View PubMed
  13. Brouwer OR, Albersen M, Parnham A, Protzel C, Pettaway CA, Ayres B, Antunes-Lopes T, Barreto L, Campi R, Crook J, Fernandez-Pello S, Greco I, van der Heijden MS, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Garcia-Perdomo HA, Rumble RB, Sachdeva A, Sakalis VI, Zapala L, Sanchez Martinez DF, Spiess PE, Tagawa ST. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol. 2023 Jun; 83 (6):548-560 Epub 2023 Mar 10
    View PubMed
  14. Lewis AR, Costello BA, Quevedo F, Pagliaro LC, Sanhueza C, Weinshilboum RM, Kalari KR, Wang L, Kohli M, Tan W, Giridhar KV. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2023 May; 83 (7):649-655 Epub 2023 Mar 16
    View PubMed
  15. May M, Lebentrau S, Ayres B, Albersen M, Protzel C, Chahoud J, Brouwer OR, Pettaway CA, Pagliaro LC, Necchi A, Watkin N, Hakenberg OW, Spiess PE. The Goal of Achieving High-Quality Surgical First-Line Therapy in Patients with Penile Cancer Is Important; However, Some Collective Efforts Are Still Required in Order to Reach It. Comment on Brassetti et al. Combined Reporting of Surgical Quality and Cancer Control after Surgical Treatment for Penile Tumors with Inguinal Lymph Node Dissection: The Tetrafecta Achievement. Curr. Oncol. 2023, 30, 1882-1892. Curr Oncol 2023 Apr 19; 30 (4):4269-4274
    View PubMed
  16. Joyce DD, Wymer KM, Sharma V, Moriarty JP, Borah BJ, Geynisman DM, Plimack ER, Costello BA, Pagliaro LC, Boorjian SA. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. Cancer. 2022 Dec 15; 128 (24):4194-4202 Epub 2022 Oct 17
    View PubMed
  17. Alamiri J, Britton CJ, Ahmed ME, Andrews JR, Higa JL, Dundar A, Karnes RJ, Kwon E, Lowe VJ, Kendi AT, Bold MS, Pagliaro LC. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. Prostate. 2022 Dec; 82(16):1483-1490. Epub 2022 Sep 11.
    View PubMed
  18. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation Therapy in Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):684-692 Epub 2022 July 22
    View PubMed
  19. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines(R) Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug; 20 (8):866-878
    View PubMed
  20. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022 Jul; 23 (7):899-909 Epub 2022 June 09
    View PubMed
  21. Pagliaro LC, Hawk M. When shall I ask for a second opinion in specialized centers and how can I find them? Do I need a medical therapy in my disease course?. Seminars in Oncology Nursing. 2022 Jun; 38 (3):151287
  22. Sakalis VI, Campi R, Barreto L, Perdomo HG, Greco I, Zapala L, Kailavasan M, Antunes-Lopes T, Marcus JD, Manzie K, Osborne J, Ayres B, Moonen LMF, Necchi A, Crook J, Oliveira P, Pagliaro LC, Protzel C, Parnham AS, Albersen M, Pettaway CA, Spiess PE, Tagawa ST, Rumble RB, Brouwer OR. What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. Eur Urol Open Sci. 2022 Jun; 40:58-94 Epub 2022 May 02
    View PubMed
  23. Pagliaro LC, Hawk M. When Shall I Ask for a Second Opinion in Specialized Centers and How Can I Find Them? Do I Need a Medical Therapy in My Disease Course? Semin Oncol Nurs. 2022 Jun; 38 (3):151287 Epub 2022 May 30
    View PubMed
  24. Orme JJ, Pagliaro LC, Quevedo JF, Park SS, Costello BA. Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist. 2022 Mar 4; 27 (2):110-124
    View PubMed
  25. Bilen MA, Rini BI, Voss MH, Larkin J, Haanen JBAG, Albiges L, Pagliaro LC, Voog EG, Lam ET, Kislov N, McGregor BA, Lalani AA, Huang B, di Pietro A, Krulewicz S, Robbins PB, Choueiri TK. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clin Cancer Res. 2022 Feb 15; 28 (4):738-747
    View PubMed
  26. Xie Z, Yadav S, Lohse CM, Cheville JC, Pagliaro LC, Shah PH, Boorjian SA, Thompson H, Leibovich BC, Costello BA. Collecting duct carcinoma: A single-institution retrospective study. Urol Oncol. 2022 Jan; 40 (1):13.e9-13.e18 Epub 2021 Nov 06
    View PubMed
  27. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  28. Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, Husnain M, Narasimhulu DM, Mathew J, Sipra QUAR, Vandvik PO, Joseph RW, Liu H, Wang Z, Herasevich V, Singh P, Hussain SA, Ho TH, Bryce AH, Pagliaro LC, Murad MH, Costello BA. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021 Dec; 80 (6):712-723 Epub 2021 Apr 03
    View PubMed
  29. Pal SK, McGregor B, Suarez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 Nov 20; 39 (33):3725-3736 Epub 2021 Sept 07
    View PubMed
  30. Childs DS, Quevedo JF, Costello BA, Pagliaro LC. Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series. Anticancer Drugs. 2021 Oct 1; 32 (9):986-990
    View PubMed
  31. Fong L, Morris MJ, Sartor O, Higano CS, Pagliaro L, Alva A, Appleman LJ, Tan W, Vaishampayan U, Porcu R, Tayama D, Kadel EE 3rd, Yuen KC, Datye A, Armstrong AJ, Petrylak DP. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4746-4756. Epub 2021 Jun 09.
    View PubMed
  32. Wee CE, Costello BA, Orme JJ, Quevedo JF, Pagliaro LC. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience. Prostate. 2021 Sep; 81 (13):938-943 Epub 2021 July 12
    View PubMed
  33. Ahmed ME, Joshi VB, Badawy M, Pagliaro LC, Karnes RJ, Lowe V, Thorpe MP, Kwon ED, Kendi AT. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. Clin Genitourin Cancer. 2021 Jun; 19 (3):223-229 Epub 2021 Jan 07
    View PubMed
  34. Wymer KM, Sharma V, Saigal CS, Chamie K, Litwin MS, Packiam VT, Mossanen M, Pagliaro LC, Borah BJ, Boorjian SA. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder. J Urol. 2021 May; 205 (5):1326-1335 Epub 2020 Dec 21
    View PubMed
  35. Mehra NS, Ho TP, Herrera Hernandez L, Quevedo JF, Costello BA, Pagliaro LC. Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. Urol Case Rep. 2020 Nov; 33:101278 Epub 2020 May 24
    View PubMed
  36. Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, Nowakowski GS, Wang ML, Wang Y. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Aug 3; 3 (8):e2012534 Epub 2020 Aug 03
    View PubMed
  37. Choo R, Nehra A, Zattoni F, Pagliaro LC, Karnes RJ. Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis? Minerva Urol Nefrol. 2020 Aug; 72 (4):474-481 Epub 2019 July 25
    View PubMed
  38. Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? J Urol. 2020 Jun; 203 (6):1147-1155 Epub 2020 Jan 13
    View PubMed
  39. Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Reply by Authors. J Urol 2020 Jun; 203 (6):1155 Epub 2020 Mar 16
    View PubMed
  40. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar; 18 (3):329-354
    View PubMed
  41. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Jul 1; 5 (7):1008-1019
    View PubMed
  42. Bryce AH, Egan JB, Smadbeck JB, Johnson SH, Murphy SJ, Harris FR, Halling GC, Terra SBSP, Cheville J, Pagliaro L, Leibovich B, Costello BA, Vasmatzis G. Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. Sci Rep. 2019 Mar 5; 9 (1):3586 Epub 2019 Mar 05
    View PubMed
  43. Shenoy N, Bhagat TD, Cheville J, Lohse C, Bhattacharyya S, Tischer A, Machha V, Gordon-Mitchell S, Choudhary G, Wong LF, Gross L, Ressigue E, Leibovich B, Boorjian SA, Steidl U, Wu X, Pradhan K, Gartrell B, Agarwal B, Pagliaro L, Suzuki M, Greally JM, Rakheja D, Thompson RH, Susztak K, Witzig T, Zou Y, Verma A. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. J Clin Invest. 2019 Mar 4; 129 (4):1612-1625 Epub 2019 Mar 04
    View PubMed
  44. Barrett MT, Lenkiewicz E, Malasi S, Stanton M, Slack J, Andrews P, Pagliaro L, Bryce AH. Clonal analyses of refractory testicular germ cell tumors. PLoS One. 2019; 14 (3):e0213815 Epub 2019 Mar 14
    View PubMed
  45. Shenoy N, Mudireddy M, Vallapureddy R, Leung N, Pagliaro L, Witzig T, Ou FS, Ordog T, Cheville J, Patnaik M, Thompson RH, Tefferi A, Begna K. Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? Clin Genitourin Cancer. 2018 Dec; 16 (6):e1117-e1122 Epub 2018 June 28
    View PubMed
  46. Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. J Urol. 2018 Nov; 200 (5):1075-1081 Epub 2018 Apr 27
    View PubMed
  47. Bhindi B, Habermann EB, Mason RJ, Costello BA, Pagliaro LC, Thompson RH, Leibovich BC, Boorjian SA. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. J Urol. 2018 Sep; 200 (3):528-534 Epub 2018 Mar 21
    View PubMed
  48. Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):431-437 Epub 2018 June 01
    View PubMed
  49. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Sep; 16 (9):1041-1053
    View PubMed
  50. Shenoy N, Pagliaro L. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Eur Urol 2018 Feb; 73 (2):304-305 Epub 2017 Nov 02
    View PubMed
  51. Loriot Y, Pagliaro L, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. Eur J Cancer. 2017 Dec; 87:140-146 Epub 2017 Nov 14
    View PubMed
  52. Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017 Nov; 72 (5):660-664 Epub 2017 May 22
    View PubMed
  53. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct; 15 (10):1240-1267
    View PubMed
  54. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. 2017 Aug 10 [Epub ahead of print]
    View PubMed
  55. Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L. Low hypoxia inducible factor-1alpha (HIF-1alpha) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Cancer Res. 2017 Aug; 29 (4):374-378
    View PubMed
  56. Parker WP, Habermann EB, Day CN, Zaid HB, Frank I, Thompson RH, Tollefson MK, Boorjian SA, Pagliaro LC, Karnes RJ. Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy. Clin Genitourin Cancer. 2017 Jul 22 Epub 2017 July 22
    View PubMed
  57. Reddy JP, Pettaway CA, Levy LB, Pagliaro LC, Tamboli P, Rao P, Jayaratna I, Hoffman KE. Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma. BJU Int. 2017 Apr; 119 (4):591-597 Epub 2016 Nov 08
    View PubMed
  58. Pagliaro LC. Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors. J Clin Oncol. 2017 Apr 01; 35 (10):1036-1040 Epub 2016 Dec 19
    View PubMed
  59. Aragon-Ching JB, Pagliaro LC. New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. Am Soc Clin Oncol Educ Book. 2017; 37:330-336
    View PubMed
  60. Ravi P, Pagliaro LC. Multimodal Therapy in the Management of Advanced Penile Cancer. Urol Clin North Am. 2016 Nov; 43: (4)469-479.
    View PubMed
  61. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct; 14 (10):1213-1224
    View PubMed
  62. Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol. 2016 Sep; 27 (9):1685-95 Epub 2016 June 20
    View PubMed
  63. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 Jun 15; 122: (12)1836-43.
    View PubMed
  64. Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology. 2016 Mar; 89:83-9 Epub 2015 Dec 23
    View PubMed
  65. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int. 2016; 2016:9795269 Epub 2016 Nov 30
    View PubMed
  66. Buonerba C, Di Lorenzo G, Pond G, Carteni G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G. Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. Front Pharmacol. 2016; 7:487 Epub 2016 Dec 20
    View PubMed
  67. Thein KZ, Osai W, Tu S, Pagliaro LC, Kim J, Yeung SJ. Association between abdominal adiposity, muscle mass, and metabolic syndrome in survivors of testicular germ cell cancer Journal of Clinical Oncology. 2016; 34 (26 Suppl):250
  68. Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015 Oct 1; 75(19):4131-42. Epub 2015 Aug 17.
    View PubMed
  69. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):276-80. Epub 2015 May 26.
    View PubMed
  70. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Jul 21.
    View PubMed
  71. Wang J, Pettaway CA, Pagliaro LC. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology. 2015 May; 85(5):1104-10. Epub 2015 Mar 25.
    View PubMed
  72. Pagliaro LC. Role of chemotherapy in treatment of squamous cell carcinoma of the penis. Curr Probl Cancer. 2015 May-Jun; 39 (3):166-72 Epub 2015 Mar 31
    View PubMed
  73. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9. Epub 2015 Feb 17.
    View PubMed
  74. Reilley MJ, Pagliaro LC. Testicular choriocarcinoma: a rare variant that requires a unique treatment approach. Curr Oncol Rep. 2015 Feb; 17(2):2.
    View PubMed
  75. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 1; 121(1):69-76. Epub 2014 Aug 22.
    View PubMed
  76. Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec; 15(13):1442-50. Epub 2014 Nov 13.
    View PubMed
  77. Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int. 2014 Oct 07.
    View PubMed
  78. Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C. Management of advanced primary urethral carcinomas. BJU Int. 2014 Jul; 114(1):25-31. Epub 2014 May 22.
    View PubMed
  79. Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014 Jun; 113(6):871-7.
    View PubMed
  80. Onaiwu CO, Ramirez PT, Kamat A, Pagliaro LC, Euscher EE, Schmeler KM. Invasive extramammary Paget's disease of the bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva. Gynecol Oncol Case Rep. 2014 Apr; 8:27-9. Epub 2014 Apr 12.
    View PubMed
  81. Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME, Platinum Study Group. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106 (5)
    View PubMed
  82. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Tan Winston MD FACP *. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. Epub 2013 Nov 12
    View PubMed
  83. Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, Spiess PE. Implications for human papillomavirus in penile cancer. Urol Oncol. 2014 Jan; 32(1):53.e1-8. Epub 2013 Nov 13.
    View PubMed
  84. Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014; 7:52. Epub 2014 Aug 01.
    View PubMed
  85. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-9. Epub 2013 Oct 23.
    View PubMed
  86. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer. 2013 Oct; 49(15):3169-75. Epub 2013 Jun 26.
    View PubMed
  87. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
    View PubMed
  88. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. 2013 Oct; 31(7):1171-7. Epub 2012 Apr 24.
    View PubMed
  89. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3621-30. Epub 2013 May 06.
    View PubMed
  90. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 1; 11(5):594-615.
    View PubMed
  91. Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G. Penile cancer: current therapy and future directions. Ann Oncol. 2013 May; 24(5):1179-89. Epub 2013 Jan 04.
    View PubMed
  92. Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Current concepts in penile cancer. J Natl Compr Canc Netw. 2013 May 1; 11(5):617-24.
    View PubMed
  93. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (NCCN). Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 1; 11(4):446-75.
    View PubMed
  94. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9. Epub 2012 Jun 27.
    View PubMed
  95. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol. 2012 Nov-Dec; 30(6):879-85. Epub 2010 Oct 08.
    View PubMed
  96. Pettaway CA, Crook J, Hegarty PK, Pagliaro L. Penile cancer update 2011: a case-based approach. Urol Oncol. 2012 Nov-Dec; 30(6):956-8.
    View PubMed
  97. Osai WE, Demicco EG, Pagliaro LC. Malignant small round blue cell tumor of the kidney without EWSR1 rearrangement: report of a case and review of the literature. Clin Genitourin Cancer. 2012 Mar; 10(1):63-5. Epub 2011 Dec 06.
    View PubMed
  98. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96. Epub 2011 Feb 03.
    View PubMed
  99. Hegarty PK, Suh J, Fisher MB, Taylor J, Nguyen TH, Ivan D, Prieto VG, Pagliaro LC, Pettaway CA. Penoscrotal extramammary Paget's disease: the University of Texas M. D. Anderson Cancer Center contemporary experience. J Urol. 2011 Jul; 186(1):97-102. Epub 2011 May 14.
    View PubMed
  100. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81. Epub 2011 May 23.
    View PubMed
  101. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer. 2011 Jun 1; 117(11):2419-25. Epub 2010 Dec 29.
    View PubMed
  102. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther. 2011 Jun; 11(6):913-20.
    View PubMed
  103. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-53. Epub 2010 Nov 29.
    View PubMed
  104. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int. 2011 Mar; 107(5):741-7. Epub 2010 Sep 21.
    View PubMed
  105. Watkins JL, Atkinson BJ, Pagliaro LC. Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature. Ann Pharmacother. 2011 Feb; 45(2):e9.
    View PubMed
  106. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther. 2010 Dec; 10(12):1883-9.
    View PubMed
  107. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20; 28(24):3851-7. Epub 2010 Jul 12.
    View PubMed
  108. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology. 2010 Aug; 76(2 Suppl 1):S58-65.
    View PubMed
  109. Pagliaro LC. Testicular cancer: when less is more. Curr Oncol Rep. 2010 Jul; 12(4):271-7.
    View PubMed
  110. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol. 2010 Mar; 65(4):811-5. Epub 2010 Jan 06.
    View PubMed
  111. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 1; 116(1):57-65.
    View PubMed
  112. Svatek RS, Munsell M, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston KE, Spiess PE, Pagliaro LC, Tamboli P, Pettaway CA. Association between lymph node density and disease specific survival in patients with penile cancer. J Urol. 2009 Dec; 182(6):2721-7. Epub 2009 Oct 17.
    View PubMed
  113. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 1; 27(25):4076-81. Epub 2009 Jul 27.
    View PubMed
  114. Rodney AJ, Gombos DS, Fuller GN, Pagliaro LC, Tannir NM. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol. 2009 Aug; 32(4):448-9.
    View PubMed
  115. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8. Epub 2009 Apr 06.
    View PubMed
  116. Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr; 27(2):221-5. Epub 2008 Aug 6
    View PubMed
  117. Rodney AJ, Gombos DS, Pagliaro LC, Tannir NM. Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases. Am J Clin Oncol. 2009 Feb; 32(1):86-7.
    View PubMed
  118. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008 Dec 20; 26(36):5936-42. Epub 2008 Nov 24.
    View PubMed
  119. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. Epub 2008 Jul 17.
    View PubMed
  120. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41. Epub 2008 Mar 25.
    View PubMed
  121. Osai WE, Ng CS, Pagliaro LC. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs. 2008 Apr; 19(4):427-9.
    View PubMed
  122. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2007 Nov 7; 99(21):1613-22. Epub 2007 Oct 30.
    View PubMed
  123. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 1; 13(19):5816-24.
    View PubMed
  124. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007 Apr; 177(4):1335-8.
    View PubMed
  125. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 1; 107(9):2254-61.
    View PubMed
  126. Pagliaro LC, Perez CA, Tu SM, Daliani DD. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol. 2006 Nov-Dec; 24(6):487-91.
    View PubMed
  127. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):144-9.
    View PubMed
  128. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 1; 107(3):497-505.
    View PubMed
  129. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7.
    View PubMed
  130. Pagliaro LC, Sharma P. Review of metastatic bladder cancer. Minerva Urol Nefrol. 2006 Mar; 58(1):53-71.
    View PubMed
  131. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005 Dec; 174(6):2186-90.
    View PubMed
  132. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 1; 23(31):7904-10.
    View PubMed
  133. Leibovici D, Pagliaro L, Rosser CJ, Pisters LL. Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol. 2005 Mar; 173(3):781-3.
    View PubMed
  134. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004 Jun 1; 22(11):2108-21.
    View PubMed
  135. Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ, Travis E. Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity. Cancer Chemother Pharmacol. 2003 Dec; 52(6):477-81. Epub 2003 Jun 21.
    View PubMed
  136. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36. Epub 2003 Jul 24.
    View PubMed
  137. Pagliaro LC, Keyhani A, Liu B, Perrotte P, Wilson D, Dinney CP. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol. 2003 Nov-Dec; 21(6):456-62.
    View PubMed
  138. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol. 2003 Sep-Oct; 21(5):342-8.
    View PubMed
  139. Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ. Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk Res. 2003 Jul; 27(7):617-26.
    View PubMed
  140. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer. 2003 Jun 15; 97(12):2988-94.
    View PubMed
  141. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003 Jun 15; 21(12):2247-53.
    View PubMed
  142. Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant. 2003 Jun; 9(6):364-72.
    View PubMed
  143. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 1; 97(3):561-7.
    View PubMed
  144. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol. 2003 Jan-Feb; 21(1):21-6.
    View PubMed
  145. Amato RJ, Perez C, Pagliaro L. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer. Invest New Drugs. 2002 Nov; 20(4):413-7.
    View PubMed
  146. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002 Aug 15; 95(4):758-65.
    View PubMed
  147. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002 Jul 1; 20(13):2965-70.
    View PubMed
  148. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
    View PubMed
  149. Jendiroba DB, Klostergaard J, Keyhani A, Pagliaro L, Freireich EJ. Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine. Leuk Res. 2002 Mar; 26(3):301-10.
    View PubMed
  150. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 3; 357(9253):336-41.
    View PubMed
  151. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000 Aug 1; 89(3):615-8.
    View PubMed
  152. Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, Dinney CP. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology. 2000 Jul; 56(1):155-9.
    View PubMed
  153. Keyhani A, Huh YO, Jendiroba D, Pagliaro L, Cortez J, Pierce S, Pearlman M, Estey E, Kantarjian H, Freireich EJ. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 2000 Feb; 24(2):153-9.
    View PubMed
  154. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L, Wilson DR. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 1999 Jul-Aug; 6(4):367-72.
    View PubMed
  155. Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res. 1998 Aug; 4(8):1971-6.
    View PubMed
  156. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201.
    View PubMed
  157. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2371-6.
    View PubMed
  158. Pagliaro LC, Antelman D, Johnson DE, Machemer T, McCulloch EA, Freireich EJ, Stass SA, Shepard HM, Maneval D, Gutterman JU. Recombinant human retinoblastoma protein inhibits cancer cell growth. Cell Growth Differ. 1995 Jun; 6(6):673-80.
    View PubMed
  159. Pagliaro LC, Mancias P. Polymyositis associated with chronic myelogenous leukemia. Ann Hematol. 1994 Apr; 68(4):213-4.
    View PubMed
  160. Salem Y, Pagliaro LC, Manyak MJ. Primary small noncleaved cell lymphoma of kidney. Urology. 1993 Sep; 42(3):331-5.
    View PubMed
  161. Pagliaro LC, Stanley WS. Interphase FISH and morphologic analysis of AML. Cancer Genet Cytogenet. 1993 Jun; 67(2):95-100.
    View PubMed
  162. Pagliaro LC, Johal S. Crystal forms of CO2/Mg2+ activated and deactivated spinach ribulose bisphosphate carboxylase. Biochim Biophys Acta. 1985(831):34-9.
PST-20216489